Early SGLT-2 Inhibitor Start May Protect Kidneys After Acute Injury

Timing of SGLT-2 Inhibitor Prescriptions Linked to Kidney Outcomes

Adults with type 2 diabetes who began taking a Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor within 30 days of leaving the hospital experienced fewer severe kidney problems than those who began 31 to 90 days after discharge. The observational study examined records from 4,406 patients who required temporary dialysis during a hospital admission for acute kidney injury (AKI).

Researchers from National Taiwan University Hospital conducted the analysis using electronic health records from the TriNetX Global Collaborative Network. All participants had discontinued dialysis prior to hospital discharge and received their first prescription for an SGLT-2 inhibitor within 90 days of leaving care.

Earlier Initiation Reduced Filtration Rate Declines

To account for baseline differences, investigators paired 1,912 early-start patients with 1,912 later-start patients using propensity-score matching. Over follow-up, 74 individuals (3.9 percent) in the 30-day group experienced an adverse kidney event, compared with 119 individuals (6.2 percent) in the 31-to-90-day group.

The composite endpoint tracked progression to end-stage kidney disease, dialysis re-initiation, or an estimated glomerular filtration rate dropping below 15 mL/min/1.73 m2. The observed difference between groups stemmed primarily from fewer early-treatment patients falling below that 15 mL filtration threshold, while rates of restarting dialysis did not show a statistically significant difference.

Six-Month Safety Measures Remained Comparable Across Groups

Physicians often delay prescribing SGLT-2 inhibitors immediately after kidney injury because blood pressure and fluid levels fluctuate during early convalescence. The researchers evaluated clinical records over six months to assess whether earlier starts triggered higher rates of complications.

Monitored safety endpoints showed similar incident rates across both groups.

• Urinary tract infections and fungal infections of the genital tract
• Diabetic ketoacidosis (DKA) and episodes of low blood sugar
• Heart failure readmissions and systemic volume depletion
• Diabetic retinopathy complications

Observational Evidence Leaves Questions for Clinical Trials

The retrospective nature of the study design means the authors cannot establish a direct cause-and-effect relationship between prescription timing and preserved kidney function. Unrecorded clinical factors or physician choices may have influenced which patients received their prescriptions within the initial month.

The investigators noted that randomized clinical trials remain necessary to confirm the most effective window for starting kidney-protective therapies after severe metabolic and renal stress. Patients recovering from hospital-treated kidney injury should discuss the timing of diabetes medications directly with their nephrologist or primary clinician.